Fri, Sep 19, 2014, 9:55 AM EDT - U.S. Markets close in 6 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

  • toponder toponder May 1, 1998 2:17 PM Flag

    I am long

    (bought at 19 - ouch) but I am wondering, what is
    to prevent the existing players in the blood
    expander market from adding a little calcium and
    electrolytes if that is a better solution?

    I imaginge
    (and hope) the solution or process of making it is
    patented by Biotime or somehow protected. Does anybody
    have any feedback on this? Thanks.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • In message 1344, Canuck_101 said:

      >If
      Hextend is not a marketplace success, BTIM
      >should
      be valued at less than book value.
      >Assets on
      a balance sheet are often sold at a

      >discount. Also, most of assets are cash and
      >they
      are rapidly going through it. Their only

      >solution is a secondary offering which in
      >effect
      takes "value" from the existing
      >shareholders to
      raise cash.

      Point taken, however, my point was
      that
      Asensio wasn�t being misleading when he was

      describing BioTime�s balance sheet when he was
      putting a
      value on the company, given that he
      believes that
      Hextend will be a failure

      In message 1344,
      Canuck_101 said:

      >Does anyone else think that
      there will be
      >some additional dilutive
      financing before
      >Hextend is brought to
      market?

      Check out their latest 10Q. BioTime had about
      6
      million in cash at the end of the year, and
      in the
      last three months of �97 they had 1.2
      million in
      expenses, 0.4 of which were
      administrative, which works
      out to 4.8 per
      year, 1.6 of which is
      administrative. However,
      they just finished their phase III,
      so I gotta
      believe that their R&D expenses are
      going to
      drop significantly.

      It doesn�t seem
      like they *need* to issue more
      stock, unless they
      want to fund more trials,
      e.g. for Pentalyte or to
      try to demonstrate
      that Hextend is superior to
      other hetastarch
      solutions. If the stock jumps up
      above 20
      again, I think it would be a good
      opportunity
      for BioTime to raise money.

    • Where is the border patrol when we need them??? Go kiss the Queens fanny!!

    • If Hextend is not a marketplace success, BTIM
      should be valued at less than book value. Assets on a
      balance sheet are often sold at a discount. Also, most of
      BTIM's assets are cash and they are rapidly going
      through it. Their only solution is a secondary offering
      which in effect takes "value" from the existing
      shareholders to raise cash.

      Does anyone else think that
      there will be some additional dilutive financing before
      Hextend is brought to market?

    • Toponder:

      You asked: "What is to prevent
      the existing players in the blood expander market
      from adding a little calcium and electrolytes if that
      is a better solution? I imagine (and hope) the
      solution or process of making it is patented by Biotime or
      somehow protected."

      Biotime's solutions are
      patented. BTIM owns 8 patents, 6 of which cover their
      solutions. You may look up the patents at the US Patent and
      Trademark Office website. I think the URL is:
      http://www.uspto.gov or if this is incorrect use a search engine. Once
      you're at the PTO website do a patent search using
      "Biotime" as the Assignee Name and let the search cover all
      years, not just 97/98.

      By the way, this points up
      another untruth claimed by shortseller Asensio. He states
      in his reports and news releases that BioTime "Has
      no assets." Eight patents and an Exclusive License
      Agreement with a major pharmaceutical company form a
      valuable franchise indeed and are quite a set of assets.
      This is in addition to the $6 Million in cash the
      company has in the bank. If he knows BioTime owns these
      patents, he's lying to his clients. If he doesn't, he's
      incredibly negligent in his research.
      ---Mark A.
      Voelker

      • 1 Reply to MarkVoelker
      • Wow lots of posts over the weekend, so I'm sorry
        about replying to such an old message. MarkVoelker said
        the following:

        By the way, this points up
        another untruth claimed by shortseller Asensio. He
        states
        in his reports and news releases that BioTime
        "Has no assets." Eight patents and an
        Exclusive
        License Agreement with a major pharmaceutical company
        form a valuable
        franchise indeed and are quite a
        set of assets. This is in addition to the $6 Million
        in
        cash the company has in the bank. If he knows
        BioTime owns these patents, he's
        lying to his
        clients. If he doesn't, he's incredibly negligent in his
        research.
        ---Mark A. Voelker

        Unless a patent is
        lisenced in, whereupon a value can be placed on it, the
        patent is not counted on the balance sheet, ergo he is
        not lying, at least about the patents. This is to
        prevent companies from inflating their balance sheet by
        overvaluing their patents

 
BTX
3.64+0.09(+2.53%)9:53 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.